Elsevier

Brain Research Bulletin

Volume 161, August 2020, Pages 106-115
Brain Research Bulletin

Transient gain of function of cannabinoid CB1 receptors in the control of frontocortical glucose consumption in a rat model of Type-1 diabetes

https://doi.org/10.1016/j.brainresbull.2020.05.004Get rights and content

Highlights

  • Frontocortical glucose uptake is smaller early after type-1 diabetes (T1D) induction.

  • The recovery from neuroglycopenia in T1D is cannabinoid CB1 receptor-dependent.

  • T1D induction is followed by a biphasic change in CB1R levels and insulin signalling.

Abstract

Here we aimed to unify some previous controversial reports on changes in both cannabinoid CB1 receptor (CB1R) expression and glucose metabolism in the forebrain of rodent models of diabetes. We determined how glucose metabolism and its modulation by CB1R ligands evolve in the frontal cortex of young adult male Wistar rats, in the first 8 weeks of streptozotocin-induced type-1 diabetes (T1D). We report that frontocortical CB1R protein density was biphasically altered in the first month of T1D, which was accompanied with a reduction of resting glucose uptake ex vivo in acute frontocortical slices that was normalized after eight weeks in T1D. This early reduction of glucose uptake in slices was also restored by ex vivo treatment with both the non-selective CB1R agonists, WIN55212−2 (500 nM) and the CB1R-selective agonist, ACEA (3 μM) while it was exacerbated by the CB1R-selective antagonist, O-2050 (500 nM). These results suggest a gain-of-function for the cerebrocortical CB1Rs in the control of glucose uptake in diabetes. Although insulin and IGF-1 receptor protein densities remained unaffected, phosphorylated GSKα and GSKβ levels showed different profiles 2 and 8 weeks after T1D induction in the frontal cortex. Altogether, the biphasic response in frontocortical CB1R density within a month after T1D induction resolves previous controversial reports on forebrain CB1R levels in T1D rodent models. Furthermore, this study also hints that cannabinoids may be useful to alleviate impaired glucoregulation in the diabetic cortex.

Introduction

Marihuana has long been known to modulate carbohydrate metabolism in animal models (de Pasquale et al., 1978) and man (Benowitz et al., 1976). One of the major targets of marihuana’s Δ9-THC in the body is the cannabinoid CB1 receptor (CB1R), the foremost metabotropic receptor of the endocannabinoid system, and is widely expressed in most mammalian organs and tissues, including the CNS, the pancreas, the liver and the skeletal muscle (Katona and Freund, 2012; Solymosi and Köfalvi, 2017). The CB1R is a major regulator of the body’s energy homeostasis, via three major targets: neural circuits, neurohumoral communication and cellular metabolism (Piazza et al., 2017; Ruiz de Azua and Lutz (2019)).

Overactivation of the endocannabinoid system may lead to systemic insulin resistance (Bowles et al., 2015; Jourdan et al., 2017; Sidibeh et al., 2017), which is a primary pathomechanism of diabetes. One theory suggests that the CB1R inhibits insulin receptor signaling via physical complexing, that is, heteromerization (Dalton and Howlett, 2012; Kim et al., 2012). Indeed, we found in the rat nucleus accumbens that the CB1R co-immunoprecipitates with the insulin receptor, and its activation prevents insulin from stimulation of [3H]deoxyglucose uptake (Pinheiro et al., 2016). Interestingly, the interaction between insulin and endocannabinoids is even more intricate. For instance, insulin stimulates endocannabinoid release in the ventral tegmental area (Labouèbe et al. (2013)), while the CB1R stimulates insulin secretion in the endocrine pancreas (Bermúdez-Silva et al., 2016). This heralds the possibility that diabetes could be associated with alterations in CB1R signaling.

Our particular area of interest is the cerebral cortex because of the widely accepted but little understood link between systemic metabolic diseases and neurodegeneration (Duarte, 2015; Rehni and Dave, 2018). It has been speculated that cerebral dysmetabolism can contribute to the onset of brain disorders (de Ceballos and Köfalvi, 2017; Zilberter and Zilberter, 2017), prompting the interest to identify new pharmacological targets to mitigate brain dysmetabolism. Recently we reported that untreated type-1 diabetes (T1D) triggered a reduction both in CB1R density and in glucose uptake in hippocampal and frontocortical slices of mice. Furthermore, the genetic deletion of the CB1R also caused similar glucose dysmetabolism, but strikingly, no further impairment was observed in the diabetic CB1R knockout animals (Moura et al., 2019). This strongly suggests that CB1R dysfunction may mediate some deleterious effects of T1D on brain glucose metabolism.

We now used ex vivo frontocortical tissue from control and diabetic rats to compare glucose metabolism, CB1R density, and the effect of CB1R ligands at 2, 4 and 8 weeks after a single i.p. injection with streptozotocin (STZ) or vehicle. We found that all the investigated parameters significantly change according to the time-course of the disease and that acute ex vivo CB1R stimulation may prevent early dysregulation of glucose metabolism in the frontocortical slices.

Section snippets

Animals and diabetes models

All studies were conducted in accordance with the principles and procedures outlined as "3Rs" in EU guidelines (86/609/EEC), FELASA, and the National Centre for the 3Rs (the ARRIVE; Kilkenny et al., 2010), and were approved by the Animal Care Committee of the Center for Neuroscience and Cell Biology of the University of Coimbra, Portugal. We also applied the ARRIVE guidelines for the design and execution of in vitro experiments (see below), as well as for data management and interpretation (

Glucose uptake in frontocortical slices of diabetic rats

The subjects of the following assay are rats in which diabetes was elicited with 1 single i.p. injection of STZ at 12 weeks of age, together with their sham-injected controls. SFig. 1 documents that the STZ-injected rats became in fact diabetic. The sham rats showed steadily increasing body weight, while the STZ-injected rats showed a reverse tendency. Blood glucose levels were highly elevated in the diabetic animals.

The following assay was carried out in pairwise manner, that is, randomly

Discussion

We here report a transient reduction of basal glucose uptake and its recovery in a CB1R-dependent fashion, in the frontal cortex of rats in the first weeks after T1D induction. We also found biphasic changes in CB1R receptor protein levels and GSK3 signaling. These changes appear counter-regulatory and sequential. Namely, after 2 weeks with T1D, the CB1R showed an increased density and a gain-of-function, as inferred from the stimulatory effect of the cannabinoid agonist, WIN55212−2. After 4

Concluding remarks

We previously reported in mice (Moura et al., 2019) and now we found in the rat that the CB1R is involved in cerebral hypometabolism in T1D. The present data suggest that targeting cerebral CB1Rs in T1D could be an interesting strategy to correct neuroglycopenia. We previously proposed a set of testable hypotheses about the mechanisms underlying the influence of CB1Rs on hippocampal and cortical glucose uptake (Moura et al., 2019). It would require a sizable effort to explore these hypotheses

Funding

This work was financed by Portuguese national funds via FCT – Fundação para a Ciência e a Tecnologia, under projects PTDC/DTP-FTO/3346/2014 (A.K.), PTDC/SAU-NSC/110,954/2009 (IT), EXCL/DTP-PIC/0069/2012 (E.C.), Centro 2020 Regional Operational Programme (CENTRO-01−0145-FEDER-000008: BrainHealth 2020) (F.I.B and F.A.A.), FEDER (QREN), through Programa Operacional Factores de Competitividade −COMPETE 2020 (POCI-01−0145-FEDER-007,440), HealthyAging2020 CENTRO-01−0145-FEDER-000,012-N2323P30 and

Declaration of Competing Interest

The authors declare no conflict of interest. The funding agencies had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References (70)

  • L. Hao et al.

    A long noncoding RNA LOC103690121 promotes hippocampus neuronal apoptosis in streptozotocin-induced type 1 diabetes

    Neurosci. Lett.

    (2019)
  • T. Jourdan et al.

    Decreasing CB1 receptor signaling in Kupffer cells improves insulin sensitivity in obese mice

    Mol. Metab.

    (2017)
  • C. Lemos et al.

    Impaired hippocampal glucoregulation in the cannabinoid CB1 receptor knockout mice as revealed by an optimized in vitro experimental approach

    J. Neurosci. Methods

    (2012)
  • E.C. McNay et al.

    Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance

    Neurobiol. Learn. Mem.

    (2010)
  • A.D. Mooradian et al.

    Brain uptake of glucose in diabetes mellitus: the role of glucose transporters

    Am. J. Med. Sci.

    (1991)
  • L.I.F. Moura et al.

    Chronic insulinopenia/hyperglycemia decrease cannabinoid CB1 receptor density and impair glucose uptake in the mouse forebrain

    Brain Res. Bull.

    (2019)
  • P.V. Piazza et al.

    The CB1 receptor as the cornerstone of exostasis

    Neuron

    (2017)
  • B.S. Pinheiro et al.

    Hierarchical glucocorticoid-endocannabinoid interplay regulates the activation of the nucleus accumbens by insulin

    Brain Res. Bull.

    (2016)
  • G. Vera et al.

    Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes

    Pharmacol. Biochem. Behav.

    (2012)
  • L. Weiss et al.

    Cannabidiol arrests onset of autoimmune diabetes in NOD mice

    Neuropharmacology

    (2008)
  • R. Abdul-Ghani et al.

    Effect of insulin on 3H-deoxyglucose uptake into brain slices and synaptosomal preparations from different brain regions

    Eur. J. Sci. Res.

    (2007)
  • F. Barutta et al.

    Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy

    Diabetes

    (2010)
  • Y. Benomar et al.

    Insulin and leptin induce Glut4 plasma membrane translocation and glucose uptake in a human neuronal cell line by a phosphatidylinositol 3-Kinase- dependent mechanism

    Endocrinology

    (2006)
  • N.L. Benowitz et al.

    Depression of growth hormone and cortisol response to insulin-induced hypoglycemia after prolonged oral delta-9-tetrahydrocannabinol administration in man

    J. Clin. Endocrinol. Metab.

    (1976)
  • F.J. Bermúdez-Silva et al.

    The cannabinoid CB1 receptor and mTORC1 signalling pathways interact to modulate glucose homeostasis in mice

    Dis. Model. Mech.

    (2016)
  • E.M. Bingham et al.

    The role of insulin in human brain glucose metabolism: an 18fluoro-deoxyglucose positron emission tomography study

    Diabetes

    (2002)
  • N.P. Bowles et al.

    A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome

    Proc. Natl. Acad. Sci. U.S.A.

    (2015)
  • J.C. Brüning et al.

    Role of brain insulin receptor in control of body weight and reproduction

    Science

    (2000)
  • I. Cranston et al.

    Changes in regional brain (18)F-fluorodeoxyglucose uptake at hypoglycemia in type 1 diabetic men associated with hypoglycemia unawareness and counter-regulatory failure

    Diabetes

    (2001)
  • M.J. Curtis et al.

    Experimental design and analysis and their reporting: new guidance for publication in BJP

    Br. J. Pharmacol.

    (2015)
  • G.D. Dalton et al.

    Cannabinoid CB1 receptors transactivate multiple receptor tyrosine kinases and regulate serine/threonine kinases to activate ERK in neuronal cells

    Br. J. Pharmacol.

    (2012)
  • M.L. de Ceballos et al.

    Boosting brain glucose metabolism to fight neurodegeneration?

    Oncotarget

    (2017)
  • A. de Pasquale et al.

    The influence of cannabis on glucoregulation

    Bull. Narc.

    (1978)
  • V. Di Marzo et al.

    Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes

    Handb. Exp. Pharmacol.

    (2011)
  • C. Díaz-Asensio et al.

    Type 1 diabetes alters brain cannabinoid receptor expression and phosphorylation status in rats

    Horm. Metab. Res.

    (2008)
  • 1

    Present addresses: VIB Discovery Sciences, Bio-incubator Leuven, 3001 Leuven (Heverlee), Belgium.

    2

    Present addresses: Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Professor Gama Pinto, Lisbon 1649-003, Portugal.

    3

    Present addresses: Post-Graduation Program in Biochemistry, Federal University of Santa Catarina, Florianópolis, Brazil.

    4

    Present addresses: Experimental Psychiatry Unit, Center for Psychiatry and Psychotherapy, Medical University Innsbruck, Austria.

    5

    Present addresses: CERVO Brain Research Center, Université Laval, Quebec City, Canada.

    6

    Department of Psychiatry and Neuroscience, Faculty of Medicine..

    7

    These authors contributed to this paper equally.

    View full text